Abstract:The increasing rates of obesity have led to elevated rates of non-alcoholic fatty liver diseases (NAFLD), which can progress to non-alcoholic steatohepatitis (NASH) and liver fibrosis, liver cirrhosis, and possibly cancer. The hepatic stellate cells (HSCs) have been considered major players in fibrogenesis in liver damage that leads to irreversible scarring. The activation of HSCs occurs as a liver injury signal via transforming growth factor β (TGF-β), which then causes the cells to proliferate and shed their extracellular matrixes. FoxS1, a barely studied transcription factor, was recently found to be increased by tumor growth factor-β (TGF-β) signaling. However, the role of FoxS1 in liver fibrosis has never been demonstrated. Our Real-Time PCR data showed that FoxS1 mRNA was increased in human cirrhotic livers that have significantly higher TGF-β, as well as in a murine model of liver fibrosis. Therefore, we hypothesize that the TGF-β-induction of FoxS1 is an essential process of HSCs activation that leads to hepatic fibrosis and scarring. To test this hypothesis, we created a FoxS1 CRISPR knockout (FoxS1 KO) and scrambled control LX2 cell lines, which are the standard human HSCs used for studying hepatic fibrosis. Then, we performed TGF-β treatments and extracted RNA for RNA sequencing and bioinformatic analysis to determine genes and pathways that are altered by the loss of the FoxS1 transcription factor. Our data demonstrate that FoxS1 regulates genes involved in collagen-containing extracellular matrix pathways, indicating that suppression of FoxS1 might prevent liver scarring. However, more work is needed in animal models to make this determination. In conclusion, these data demonstrate that FoxS1 induces liver fibrosis and plays a critical role in TGF-β-induced human HSC-extracellular matrix production that occurs during hepatic scarring. Based on the findings, FoxS1 may serve as a new therapeutic target for liver fibrosis. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

UCHL1-dependent control of Hypoxia-Inducible Factor Transcriptional Activity during Liver Fibrosis

Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis

Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication

Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice

Hypoxia‐inducible Factor‐dependent Production of Profibrotic Mediators by Hypoxic Hepatocytes

Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis

Heterogeneity of Hepatic Stellate Cells in Fibrogenesis of the Liver: Insights from Single-Cell Transcriptomic Analysis in Liver Injury

Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis

Hepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammation and TGF-β1-mediated HSC Activation

The forkhead box F1 transcription factor inhibits collagen deposition and accumulation of myofibroblasts during liver fibrosis

Wnt signaling in liver fibrosis: progress, challenges and potential directions

The HLF/IL-6/STAT3 Feedforward Circuit Drives Hepatic Stellate Cell Activation to Promote Liver Fibrosis

Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis

From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells

FoxS1 is a Novel Mediator of Hepatic Fibrosis Through Transcriptional Control of the Extracellular Matrix

Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis

Single‐cell RNA sequencing reveals the heterogeneity and intercellular communication of hepatic stellate cells and macrophages during liver fibrosis

Altered AP-1, RUNX, and EGR chromatin dynamics drive fibrotic lung disease

Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis

Expanded transcriptomic analysis of human hepatic stellate cells links novel coding and noncoding products to human liver fibrosis

Cellular basis of hepatic fibrosis and its role in inflammation and cancer